HC Wainwright Analysts Decrease Earnings Estimates for MLYS

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - HC Wainwright decreased their FY2024 EPS estimates for shares of Mineralys Therapeutics in a research note issued to investors on Tuesday, November 12th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($3.83) per share for the year, down from their previous estimate of ($3.22). HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Mineralys Therapeutics' Q4 2024 earnings at ($1.14) EPS, FY2025 earnings at ($4.10) EPS, FY2026 earnings at ($3.41) EPS, FY2027 earnings at ($3.54) EPS and FY2028 earnings at ($1.85) EPS.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Monday, November 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period in the prior year, the company earned ($0.57) EPS.

Mineralys Therapeutics Stock Down 0.7 %

MLYS stock traded down $0.09 during trading hours on Thursday, hitting $12.36. The company's stock had a trading volume of 114,354 shares, compared to its average volume of 179,587. The company has a market capitalization of $614.63 million, a PE ratio of -3.81 and a beta of 1.71. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $16.91. The stock has a 50 day moving average price of $12.99 and a two-hundred day moving average price of $12.65.

Institutional Trading of Mineralys Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Mineralys Therapeutics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company's stock valued at $116,000 after purchasing an additional 3,732 shares during the period. Vanguard Group Inc. boosted its holdings in Mineralys Therapeutics by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 982,932 shares of the company's stock valued at $12,690,000 after purchasing an additional 4,952 shares during the period. Federated Hermes Inc. raised its stake in shares of Mineralys Therapeutics by 100.0% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $140,000 after buying an additional 6,000 shares in the last quarter. Verition Fund Management LLC raised its stake in shares of Mineralys Therapeutics by 30.6% in the 3rd quarter. Verition Fund Management LLC now owns 27,361 shares of the company's stock valued at $331,000 after buying an additional 6,408 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Mineralys Therapeutics in the 3rd quarter valued at $110,000. 84.46% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider David Malcom Rodman sold 25,482 shares of the company's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the sale, the insider now directly owns 135,974 shares of the company's stock, valued at approximately $2,043,689.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the sale, the chief financial officer now directly owns 236,854 shares of the company's stock, valued at $3,214,108.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Malcom Rodman sold 25,482 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the sale, the insider now directly owns 135,974 shares of the company's stock, valued at approximately $2,043,689.22. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 51,510 shares of company stock valued at $735,431. Company insiders own 33.24% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.